Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Fremanezumab in Pediatric Migraine
NCT04530110Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2020
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of fremanezumab in migraine, sponsored by Teva Pharmaceutical Industries Ltd.. Started Sep 2020; status: completed.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04530110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04530110.